Baseline Characteristics of 41 Patients With Advanced Cancer Administered Placebo Plus Filgrastim or PEG-rHuMGDF Plus Filgrastim After Chemotherapy
| . | Placebo . | PEG-rHuMGDF . |
|---|---|---|
| No. of patients | 10 | 31 |
| Median age (range) | 59 (36-69) | 57 (20-74) |
| Male/Female | 7/3 | 22/9 |
| Median Karnofsky performance status (range) | 85 (70-100) | 90 (60-100) |
| Tumor type | ||
| Non–small cell lung | 3 | 12 |
| Carcinoma of unknown primary | 2 | 4 |
| Gastric | 2 | 2 |
| Kidney | 1 | 2 |
| Small cell lung | 1 | 1 |
| Carcinoid | 1 | 0 |
| Other* | 0 | 10 |
| Prior chemotherapy | 1 | 6 |
| Prior radiotherapy | 1 | 5 |
| Median (range) baseline platelet count × 109/L | 270 (139-370) | 273 (148-487) |
| . | Placebo . | PEG-rHuMGDF . |
|---|---|---|
| No. of patients | 10 | 31 |
| Median age (range) | 59 (36-69) | 57 (20-74) |
| Male/Female | 7/3 | 22/9 |
| Median Karnofsky performance status (range) | 85 (70-100) | 90 (60-100) |
| Tumor type | ||
| Non–small cell lung | 3 | 12 |
| Carcinoma of unknown primary | 2 | 4 |
| Gastric | 2 | 2 |
| Kidney | 1 | 2 |
| Small cell lung | 1 | 1 |
| Carcinoid | 1 | 0 |
| Other* | 0 | 10 |
| Prior chemotherapy | 1 | 6 |
| Prior radiotherapy | 1 | 5 |
| Median (range) baseline platelet count × 109/L | 270 (139-370) | 273 (148-487) |
Includes ovary, thyroid, esophagus, liver, colon, melanoma, bladder, pancreas.